Real-world Data From CROI: What’s New in HIV Care for Treatment-Experienced People

“Good enough” is no longer good enough when caring for treatment-experienced people with HIV. Tune in to find out what’s new in management of multidrug-resistant HIV and dig into the latest data from CROI 2026. Topics covered include: Real-world experiences with LEN in the United States and Europe for management of multidrug-resistant HIV Pharmacokinetic profiles of combined LA CAB + LEN Ibalizumab for multidrug-resistant HIV Long-term 7-year outcomes for heavily treatment–experienced people living with HIV and 4-class drug resistance To download the accompanying slides, please visit the program page: https://bit.ly/4pEenZC Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Onyema Ogbuagu, MD, FACP, FIDSA Professor of Medicine and Pharmacology Director, Yale Antivirals and Vaccines Research Program Yale School of Medicine New Haven, Connecticut Charlotte-Paige Rolle, MD, MPH Director of Research Operations Orlando Immunology Center Adjunct Assistant Professor of Global Health Emory University Rollins School of Public Health Atlanta, Georgia Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tune into this podcast, featuring audio from a live conference coverage webinar, to learn from global experts, Monica Gandhi, MD, MPH, and Jean-Michel Molina, MD, as they summarize and discuss the latest updates on HIV treatment and prevention from CROI 2026. Topics covered include: Emerging HIV treatments Advances in HIV prevention Investigational agents for HIV prevention Early-phase investigational HIV treatments For more coverage of CROI 2026, and to follow along with the downloadable slides, visit the program page:https://bit.ly/4bmS062 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Monica Gandhi, MD, MPH Professor of Medicine and Associate Chief Division of HIV, Infectious Diseases, and Global Medicine Director, UCSF Center for AIDS Research (CFAR) Director of HIV Special Program "Ward 86" HIV Clinic San Francisco General Hospital San Francisco, California Jean-Michel Molina, MD Professor of Medicine Saint-Louis and Lariboisire Hospitals Université Paris Cité Paris, France   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cytomegalovirus (CMV) infection is one of the most significant infectious complications after hematopoietic cell transplant (HCT), but there have been major advances in CMV management to date. In this podcast, featuring curated audio from a live satellite symposium, experts Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID, and Marcus Pereira, MD, MPH, FAST, discuss considerations for CMV treatment in HCT recipients and examine treatment options for refractory/resistant CMV. Topics include: Considerations for CMV management in HCT recipients New definitions of refractory and resistant CMV  Risk factors for refractory and resistant CMV infections Identifying drug-resistant CMV  Treatment options for refractory/resistant CMV To view the full educational program and download the accompanying slides, visit our website:https://bit.ly/4lfrDTT Presenters: Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID Professor and Chair G.P. Bodey, Sr. Distinguished Professorship in Infectious Diseases President, The International Immunocompromised Host Society (ICHS) Director, Clinical Virology Research Department of ID/IC/EH UT MD Anderson Cancer Center Houston, Texas Marcus Pereira, MD, MPH, FAST Associate Professor of Medicine Director of Clinical Services, Division of Infectious Diseases Medical Director, Transplant Infectious Disease Program Columbia University Irving Medical Center New York, New York Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cytomegalovirus (CMV) infection is one of the most significant infectious complications after hematopoietic cell transplant (HCT). In this podcast, featuring curated audio from a live satellite symposium, experts Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID and Marcus Pereira, MD, MPH, FAST, discuss the burden of CMV in HCT recipients and explore strategies effectively identify and monitor high-risk patients. Topics include: Epidemiology of CMV among HCT recipients Direct and indirect effects of CMV after HCT Dynamics of risk factors for CMV infection  Strategies for prevention of CMV infection To view the full educational program and download the accompanying slides, visit our website:https://bit.ly/4lfrDTT Presenters: Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID Professor and Chair G.P. Bodey, Sr. Distinguished Professorship in Infectious Diseases President, The International Immunocompromised Host Society (ICHS) Director, Clinical Virology Research Department of ID/IC/EH UT MD Anderson Cancer Center Houston, Texas Marcus Pereira, MD, MPH, FAST Associate Professor of Medicine Director of Clinical Services, Division of Infectious Diseases Medical Director, Transplant Infectious Disease Program Columbia University Irving Medical Center New York, New York Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, experts Jacinda (JAM) Abdul-Mutakabbir, PharmD, MPH; Ruth Carrico, PhD, DNP, FNP-C, FAAN; and Dalilah Restrepo, MD, discuss improving shingles vaccine uptake. Topics covered include: The Burden of ShinglesCare Coordination Between Primary and Specialty CarePromoting Shingles Vaccine Series CompletionAddressing Disparities in Shingles Vaccine Access and Uptake Presenters:Jacinda (JAM) Abdul-Mutakabbir, PharmD, MPHAssociate Professor of Clinical PharmacyUniversity of California, San DiegoDepartment of Pharmacy Practice and Sciences, Skaggs School of Pharmacy and Pharmaceutical SciencesDivision of the Black Diaspora and African American StudiesLa Jolla, CaliforniaRuth Carrico, PhD, DNP, FNP-C, FAANSenior PartnerCarrico & Ramirez PLLCProfessor, AdjunctDivision of Infectious DiseasesUniversity of Louisville School of MedicineLouisville, KentuckyDalilah Restrepo, MDInfectious Diseases SpecialistUniversity of California, IrvineLos Alamitos HospitalOrange County, California Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Historically, key symptoms of primary biliary cholangitis (PBC), such as pruritus and fatigue, have been understudied and undertreated. Listen now to learn how symptom management should be considered independently of PBC management, and how new therapeutic agents can help.Topics covered include:Mechanisms of pruritus and fatigue in PBCNonpharmacologic treatment optionsAn overview of clinical trial data supporting second-line agents for symptom management:BezafibrateElafibranorSeladelparInvestigational agents:VolixibatLinerixibatSetanaxibThis episode is the third of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode:https://bit.ly/44ZJ5osPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New therapeutic agents for second-line treatment are raising the bar for primary biliary cholangitis (PBC) management. Listen now to learn how to incorporate these new agents into clinical practice and how these agents will impact attainment of treatment goals.Topics covered include:Available agents for second-line treatment of PBCAn overview of clinical trial data supporting second-line agents:Obeticholic acid (OCA)BezafibrateElafibranorSeladelparThis episode is the second of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/48MEc3rPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advancements in our understanding of primary biliary cholangitis (PBC) and new therapeutic agents have reshaped the care landscape of PBC. Listen now to learn how these developments are helping to redefine and elevate treatment goals. Topics covered include:How and when to assess treatment responseRisk factors in PBCBiochemical treatment response and fibrosis stage as predictors of transplant-free survivalDynamics of liver stiffness measurements and clinical outcomes in PBCThe importance of bilirubin and alkaline phosphatase normalizationThis episode is the first of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/44ZJ5osPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tune in to listen as expert faculty, Dr Christopher L. Bowlus and Dr Sonal Kumar, discuss recent developments in treating primary biliary cholangitis (PBC) with new and emerging agents, as well as strategies to integrate these advances into clinical practice.Topics covered include: Methods of Assessing PBC Disease ProgressionNewer Agents for Second-line Treatment of PBCPrioritizing Symptom Management and Quality of Life With PBC TreatmentPresenters:Christopher L. Bowlus, MDLena Valenta Professor and ChiefDivision of Gastroenterology and HepatologySchool of Medicine University of California Davis Sacramento, CaliforniaSonal Kumar, MD, MPHAssistant Professor of MedicineDivision of Gastroenterology and HepatologyWeill Cornell Medical CollegeNew York, New YorkLink to full program: https://bit.ly/43nHx6UGet access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen in as Nancy Reau, MD, reviews key highlights of the most impactful primary biliary cholangitis (PBC) research and gain insights on how to apply these new advances to clinical practice. Topics covered include:Treatment GoalsLong-term Data With PPAR AgonistsInvestigational Therapies for PruritusPresenter: Nancy Reau, MDProfessor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical CenterChicago, IllinoisTo download the accompanying slides, visit the program page for this episode: https://bit.ly/4b2d6YD Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.